SuperworthKalaris Therapeutics EPS KLRS
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$0.48
- Fiscal year 2024
- −$38.66
Kalaris Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$0.48.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2024 | −$38.66 | n/a |
| FY2023 | −$42.09 | n/a |
| FY2022 | −$52.67 | n/a |
| FY2021 | −$62.79 | n/a |
| FY2020 | −$221.49 | n/a |
| FY2019 | −$414.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.48 | n/a | n/a | |
| Q1 FY26 | −$0.46 | n/a | n/a | |
| Q3 FY25 | −$0.64 | n/a | −$7.41 | |
| Q2 FY25 | −$0.61 | n/a | −$34.93 | |
| Q1 FY25 | −$2.52 | n/a | −$38.58 | |
| Q4 FY24 | −$3.64 | n/a | −$38.66 | |
| Q3 FY24 | −$28.16 | n/a | −$46.98 | |
| Q2 FY24 | −$4.26 | n/a | −$27.79 | |
| Q1 FY24 | −$2.60 | n/a | −$34.57 | |
| Q4 FY23 | −$11.96 | n/a | −$42.09 | |
| Q3 FY23 | −$8.97 | n/a | −$39.56 | |
| Q2 FY23 | −$11.04 | n/a | −$42.09 |
Against its peers
Companies in Healthcare nearest Kalaris Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KLRSKalaris Therapeutics | n/m | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| NEPHNephros | $0.16 | +33% a year |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Kalaris Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.